

Name: Kittelson, John

Mailing Address:

Email Address:

Board Name: Bicycle & Pedestrian Advisory Board

Daytime Phone:

Alternate Contact Phone:

Is your mailing address different than your physical address?:

No

Physical Address:

Zip Code:

How long have you been a city resident?:

3.5 years

In which ward do you reside?:

Ward 4

Are you registered to vote?:

Yes

Current Occupation:

Retired Professor (University of Colorado)

Current Employer:

Retired

Briefly describe your educational background:

Pomona College: B.A., Biology, 1977 University of Minnesota: M.S., Statistics, 1987

University of Arizona: Ph.D. Statistics, 1996

List of community service experience:

Missoula community service (April 2021-Present): Volunteer at Free Cycles bike building events; Volunteer at MTCX cycling events; Big Sky Beekeepers: Club Secretary/Communications; Missoula Nordic Ski club: Trail groomer; Co-founder of the Zootown Ebike Club.

What is your interest in serving on this board, commission or committee?:

I am interested in working to expand and improve Missoula's cycling infrastructure and amenities. I co-founded the Zootown Ebike Club in order to facilitate bi-directional communication between the ebike community and Missoula's land use planners. I would like to serve on the Bicycle & Pedestrian Advisory Board for two main reasons: (1) to be more effective at engaging cyclists in providing input to new city/county projects and long-term planning efforts, and (2) to help the city identify and prioritize the needs for cycling infrastructure and opportunities in and around Missoula.

What special knowledge, interest, or experience do you possess that would qualify you for a position on this board commission, or committee?:

I am an experienced and enthusiastic bike commuter and recreational/competitive cyclist. I have lived and biked in many cities across the US and internationally, and am interested in using my experience with good (and bad) cycling infrastructure to help expand and improve cycling infrastructure in and around Missoula. Throughout my professional career I have had to balance competing viewpoints to achieve the consensus required for meaningful progress. I look forward to working with the Bicycle & Pedestrian Advisory Board to build this type of consensus between the cycling community and Missoula's city, county, and federal land-use planners.

Reference 1 Name:

Carl Sisk

Reference 1 Phone:

Reference 2 Name:

Gary Bell

Reference 2 Phone:

Time of Submission: 09/16/24 2:16:13 PM

Attachments

- KittelsonCV.pdf

CURRICULUM VITAE

(April 2024)

Contact Information

Name: John Martin Kittelson
Work Address: Department of Biostatistics and Informatics
University of Colorado Anschutz Medical Campus

Correspondence:

E-mail:

Education

1977	B.A., Biology	Pomona College Claremont, California.
1987	M.S., Statistics	University of Minnesota Minneapolis, Minnesota.
1996	Ph.D., Statistics	The University of Arizona Tucson, Arizona.
	Dissertation title:	<i>The Design of Group Sequential Clinical Trials.</i>
	Advisor:	Scott Emerson, M.D., Ph.D.

Academic and Professional Positions

2001-Present	Department of Biostatistics and Informatics University of Colorado Denver Clinical Professor - Retired (June 2021- Present) Professor with tenure(2011- May 2021) Other positions include: Director, Biostatistics program, Clinical Translational Sciences Institute (2008-2012) Director, Colorado Biostatistics Consortium (2006-2012) Associate Professor (2005-2011) Assistant Professor (2001-2005)
1996-2001	Department of Preventive and Social Medicine University of Otago Dunedin, New Zealand Positions (lecturer to senior lecturer; listed as US equivalent ranks): Associate Professor with tenure (2001) Assistant Professor with tenure (1999-2000) Assistant Professor (1996-1999)

Academic and Professional Positions (con't)

1987-1995	Senior Biostatistician Arizona Cancer Center University of Arizona Tucson, Arizona
1980-1987	Biologist Environmental Resources Branch U.S. Corps of Engineers St. Paul, Minnesota
1978-1979	Teacher U.S. Peace Corps Apia, Western Samoa

Memberships in Professional Organizations

1987-2021	International Biometric Society
1996-2021	New Zealand Statistical Association
1985-2021	American Statistical Association

Government, Industry, and University Committee Positions

(a) Government Advisory Committees:

2010-2013	Member	FDA Advisory Committee for Reproductive Health Drugs
1998-2001	Member	Meningococcal Vaccine Efficacy Trial Advisory Group New Zealand Ministry of Health
1990	Member	North American Hyperthermia Group advisory panel U.S. Food and Drug Administration

(b) External advisory committees:

2020 - 2021	Member	Data Safety and Monitoring Board HEP-COVID trial: anticoagulation therapy for high risk COVID-19 patients.
2017 - 2020	Member	Safety Monitoring Committee: Clinical trials of Tanezumab for pain management
2016 - 2019	Member	Data Monitoring Committee: PIONEER 6: cardiovascular safety of oral semaglutide.
2014 - 2016	Member	Data Monitoring Committee: IdeaT2 trial Phase III trial in diabetes care Novo Nordisk
2014 - present	Member	Data Safety Monitoring Board: Cystic Fibrosis Foundation Therapeutics
2007-2009	Chair	Data Monitoring Committee: Phase II trial in Peripheral Arterial Disease (PAD-001) BioMarin Pharmaceutical Inc.

2007-2010	Member	Data Monitoring Committee: OCEANS trial (VGF3554g) Genentech
2006-2008	Chair	Data Monitoring Committee: Diabetic Foot Ulcer trial (VGF3554g) Genentech
2005	Chair	Data Monitoring Committee: Atopic dermatitis trial (ACD3331g) Genentech
2003-2006	Member	TROPIC/ICPOP Data Monitoring Committee KOS Pharmaceuticals
2002-2003	Member	COINART-1 Data Safety and Monitoring Committee Boehringer Ingelheim Pharmaceuticals

(c) University of Colorado Health Sciences Center Committees:

2013- 2021	Member	Biostatistics and Informatics DAPTCO, ColoradoSHP
2019- 2021	Chair	School-wide Admissions Committee, ColoradoSHP
2017-2019	Member	Colorado School of Public Health Research Committee
2015-2018	President	(3-year sequence) Faculty Senate, Colorado School of Public Health
2013-2015	Senator	Faculty Senate, Colorado School of Public Health
2008-2010	Member	Colorado Clinical Translational Sciences Institute (CCTSI) Executive Committee
2008-2010	Member	Center for AIDS Research (CFAR) Executive Committee
2006-2010	Member	School of Medicine Dean's Advisory Committee: Clinical Translational Research Advisory Committee
2006-2010	Member	BERD program steering committee
2007-2008	Member	Interim Executive Council Colorado School of Public Health
2005-2007	Member	Departmental Executive Committee
2001-2010	Member	Scientific Advisory and Review Committee (CCTSI)
2002-2008	Member	Study Monitoring Committee (CCTSI)
2002	Chair	Strategies to fund Biometrics teaching
2003-2006	Chair	Biometrics service course curriculum committee
2004-2006	Member	Biometrics Program curriculum committee
2004	Chair	Biometrics MS/PhD comp exam committee
2004	Member	School of Public Health biostatistics committee
2002	Member	Biometrics program admissions committee

(d) University of Otago committees:

2000-2001	Member	Working party on biostatistics
2000-2001	Chair	Working party on research methods teaching
2001	Chair	Working party for graduate study in biostatistics

Professional Service

- (a) International Biometrics Society (Western North American Region)
 - 2011-2013 WNAR President (3-year term: president-elect, president, past-president)
 - 2011 Organizer and chair: student paper competition
 - 2008 Judge: student paper competition
 - 2007-2009 Regional representative

- (b) Journal referee:
 - Biometrics
 - Clinical Trials
 - Statistics in Medicine
 - Journal of Sequential Analysis
 - Journal of the American Statistical Association (JASA)
 - Journal of Clinical Oncology
 - Veterinary Radiology
 - International Journal of Radiation Oncology, Biology, and Physics
 - Cancer
 - Journal of Computational Graphics and Statistics
 - JASA: Applications and Case Studies

- (c) Grant Reviews:
 - 07/2019 Special Emphasis Panel for review of U19 applications for Post-stroke vascular contributions to cognitive impairment and dementia
NIH: National Institute of Neurological Disorders and Stroke (NINDS)
 - 10/2018 Special Emphasis Panel for review of U01 applications for StrokeNet Clinical Trials and Biomarker Studies.
NIH: National Institute of Neurological Disorders and Stroke (NINDS)
 - 12/2016 Special Emphasis Panel for review of U24 applications for Network for Emergency Care Clinical Trials:
SIREN – Data Coordinating Center (DCC)
NIH: National Institute of Neurological Disorders and Stroke (NINDS)
 - 03/2014 Special study section for review of U34 applications for Clinical trial planning studies for rare thrombotic and hemostatic disorders
NIH: National Heart Lung and Blood Institute
 - 10/2010 Special study section for re-review of multi-center trial for treatment of septic shock
NIH: National Institute of General Medicine
 - 12/2009 Special study section for review of multi-center trial for treatment of septic shock
NIH: National Institute of General Medicine
 - 08/2008 Invited review of application for multi-center randomized controlled trial of Zoledronic acid for treatment of vascular abnormalities
Deutsche Forschungsgemeinschaft (German Research Foundation)

02/2008	Biostatistics Methods and Research Design Study Section National Institutes of Health; Washington DC
02/2007	SPORE in Prostate, Breast, and Skin Cancers Review National Cancer Institute; Bethesda MD
1996-1998	New Zealand Health Research Council Clinical Research Applications (Equivalent to an NIH study section)

Invited Workshops

2012-18	Sequential monitoring of clinical trials Summer Institute in Biostatistics University of Washington, Seattle
2002	Design of group sequential clinical trials University of Otago, New Zealand
2000	Designing clinical trials CSIRO, Sydney, Australia (equivalent to NSF)
1999	Workshop on the design of clinical trials International Biometric Society Meetings Hobart, Australia
1998	Group sequential trial design Clinical Trials Research Unit University of Auckland, New Zealand

Teaching

- (a) Teaching awards (Department of Preventive Medicine and Biometrics, UCD)
- | | |
|------|---|
| 2006 | Departmental award for excellence in teaching |
| 2007 | Departmental award for excellence in teaching |
- (b) Teaching Initiatives:
- New course development (UCD)*
- | | |
|-----------|---|
| 2010 | BIOS 7732 Advanced Mathematical Statistics II |
| 2004 | BIOM 6649 Statistical Methods in Clinical Trials |
| 2004 | BIOM 6648 Clinical trials |
| 2003-2005 | Research methods courses (BIOM 6601/02; PRMD 6626)
(Initiated working group on content of this course sequence) |
| 2004-2010 | Develop and run the student journal club and seminar series |
| 2014-2015 | Co-organize departmental journal club series |
| 2003-2010 | GCRC and CCTSI continuing education program:
6-week (12-hour) workshop on study design (offered annually)
6-week (12-hour) workshop on data analysis (offered annually) |

Teaching (con't)

New course development (University of Otago, New Zealand)

1997-2001	HASC 413: Biostatistics
2000	HASC 402: Applied Data Analysis
2000	HASC 402: Clinical Trials Reading Course
2001	HASC 415: Regression Methods

(c) Mentoring/Advising (UCD):

Biostatistics Doctoral Students

2005- 2019	Jim Hu (Degree awarded May 2019) Design and application of sequential clinical trials with bivariate outcomes
2007-2012	Laura Pyle (degree awarded August 2012) Sequential monitoring of longitudinal endpoints with incomplete support. University of Colorado Denver
2007-2009	Xiang Yin (degree awarded August 2009) Group sequential designs for trials with multiple treatment groups. University of Colorado Denver
2007-2009	Mark Tripputi (degree awarded August 2009) Use of mediation in designing clinical trials with multiple endpoints George Washington University Biostatistics
2004-2009	Adam Boyd (degree awarded May 2009) Censoring-robust treatment effect estimation in clinical trials with time-to-event endpoints. University of Colorado Denver
2003-2007	Patrick Blatchford (degree awarded May 2007) Monitoring trials with bivariate endpoints. University of Colorado Denver

Biostatistics Masters Students (all at UCD)

2019-2021	Conner Jackson (degree awarded June 2021) Design and analysis of cluster-randomized trials for malaria prevention in Burkina Faso
2014-2015	Elise Gunzberger (degree awarded December 2015) Application of joint longitudinal and survival models to bivariate decision making in group sequential clinical trials University of Colorado Denver
2014-2016	Jeffery R. Lambert (degree awarded May 2016) Design and implementation of group sequential clinical trials for censoring-robust hazard ratio estimators under non-proportional hazards University of Colorado Denver

- 2012-2013 Thomas Glorioso (degree awarded August 2013)
Robust inference in generalized linear models
University of Colorado Denver
- 2002-2006 Guoyi Liu
Longitudinal endpoints in group sequential clinical trials.
- 2004-2006 Xiang Yin (degree awarded December 2006)
Group sequential designs for trials with multiple treatment groups.
- 2004-2005 Shuling Li (degree awarded August 2005)
Use of mediation models for evaluation of biomarkers for lung cancer.
- 2001-2004 Sonya Heltshé (degree awarded December 2004)
Statistical efficiency in group sequential clinical trial design.

Mentor: honours thesis (University of Otago, New Zealand)

- 2000 Kylie Gilmore
Honours in Statistics; University of Otago
Improving the Efficiency for Evaluating a Novel Meningitis Vaccine.

(d) Membership on student committees (UCD):

Doctoral Dissertation Committees

- 2013-2018 Mark Manago (Clinical Sciences) PhD awarded May 2018
New insights into the role of lower extremity and trunk muscle function to gait in people with multiple sclerosis.
- 2008-2011 Brian Lowes (Clinical Sciences) PhD awarded May 2011
Genetic mechanisms in systolic dysfunction and ventricular remodeling in patients with idiopathic dilated cardiomyopathy.
- 2006-2008 Mark Jaros (Biostatistics) PhD awarded May 2008
Joint inference for longitudinal and survival endpoints.
- 2005-2007 Sonya Heltshé (Biostatistics) PhD awarded August 2007
Length-biased sampling in cancer screening trials.
- 2004-2005 Jan Lowery (Epidemiology) PhD awarded 2005
Cancer screening and interval breast cancer rates.
- 2002 Melanie Bell (Biometrics) PhD awarded 2002
The use of maximum pseudolikelihood in generalized linear mixed models for replicated spatial point patterns.
- 2002 Tim Webb (Biometrics) PhD awarded 2002
Exact test size and power for small samples using an internal pilot study.

Masters Thesis Committees (UCD)

- | | |
|-----------|---|
| 2008-2009 | Miranda Grote (Biostatistics) Degree awarded 2009
A Comparison of Methods to Test Intermediate Endpoint Effects
in Logistic Regression. |
| 2005-2006 | Erin Martinez (Biostatistics) Degree awarded 2006
Using Two Part Models for Data with a High Proportion of Zero Responses. |
| 2005-2006 | Miguel Martinez (MSPH) Degree awarded 2006
Promoter Hypermethylation in both Cancer and
in Normal Epithelium in Lung Cancer Patients. |
| 2003-2004 | Shailaja Pande (MSPH) Degree awarded 2004
Oral contraceptive use is inversely related to the presence
of serum rheumatoid factor in a healthy population. |

(e) Courses taught (UCD):

Course director

- | | |
|-----------|---|
| 2010-2021 | BIOS 7732: Advanced Mathematical Statistics II |
| 2006-2020 | BIOS 6649: Clinical Trials: Statistical Design and Monitoring |
| 2002-2017 | BIOS 6648: Design and Conduct of Clinical Research |
| 2002-2008 | BIOS 6601: Biostatistics I |

Course contributor

- | | |
|-----------|-----------------------------------|
| 2002-2021 | BIOM 6621: Statistical consulting |
| 2003-2005 | PRMD 6631: Advanced Epidemiology |
| 2002-2003 | PRMD 6603: Health Care Systems |
| 2004 | PRMD 6626: Research Methods |

(f) Courses taught (University of Otago, New Zealand):

Course director

- | | |
|-----------|--|
| 2001 | HASC 415: Regression Methods |
| 1997-2001 | HASC 413: Biostatistics |
| 2000 | HASC 402: Applied Data Analysis |
| 2000 | HASC 402: Clinical Trials |
| 1996-1998 | PHTY 306 Research Methods |
| 1996-2001 | Co-directed 6th year medical student research projects |

Course contributor

- | | |
|-----------|--|
| 1999-2001 | STAT 115 Introductory Biostatistics |
| 2000-2001 | HASC 411 Research Methods |
| 1996-2001 | HEAL 201 Introduction to Epidemiology |
| 2000-2001 | Clinical trials module for 3rd year medical students |
| 1999-2001 | Lead discussion groups critiquing published medical research |
| 1998-2001 | Statistical module for review course for medical board exams |

(g) Departmental seminars (UCD)

Seminar series organized

2014-2016	Biostatistics journal club series
2003-2009	Biometrics student seminar series
2004-2009	Biometrics student journal club
2002-2003	Departmental seminar series

Seminar presentations

2010	The predictive value of a positive trial and its implications for clinical trial networks
2004	Methods for biomarker evaluation
2003	Trial design for scientific discrimination
2002	Evaluation of screening tests

Major Grant Support/Collaborations

(a) Completed Grant Support

1R25HL147194-01 (Kittelson) 03/15/2019 to 02/28/2022

NIH-NHLBI: Colorado Summer Institute in Biostatistics (CoSIBS)

NHLBI training grant: Summer Institutes for Biostatistics Research Education for advanced undergraduate students.

Role: Co-Principal Investigator and Program Director (mPI)

NIH-NHLBI U-01 (PIs: Hiatt and Goldenberg) 01/09/2016 to 01/09/2021

DCC for the Kids-DOTT trial (ClinicalTrials.gov: NCT00687882)

Role: Lead trial biostatistician.

Institutional Contract (PI: Schwartz G) 07/01/2011 to 01/01/2020

Secondary data analyses from phase III dal-OUTCOMES trial.

Role: Lead biostatistician

VOYAGER trial (*ClinicalTrials.gov*: NCT02504216):

Efficacy and safety of rivaroxaban to reduce risk of major thrombotic vascular events events in patients with peripheral artery disease; Academic PI: William Hiatt

Role: Lead academic biostatistician

Antithrombotic Trials Leadership and Steering Group (ATLAS)

Academic thought leadership group in antithrombosis clinical trials

Role: Lead biostatistician

R25HL131486-01 (Kittelson) 01/15/2016 to 01/15/2019

NIH-NHLBI: Colorado Summer Institute in Biostatistics (CoSIBS)

NHLBI training grant: Summer Institutes for Biostatistics Research Education for advanced undergraduate students.

Role: Principal Investigator and Program Director

(a) Completed Grant Support (con't)

Colorado Clinical Translational Sciences Institute. PI: Ron Sokol; 07/08-06/12

Total Direct Costs: \$82,007,501 (CCTSI total); \$3,470,327 (Biostatistics Program)

Role: PI: Biostatistics Epidemiology and Research Design program

Institutional Startup grant (SIRC). PI: John Kittelson; 09/06-10/10.

Colorado Biostatistics Consortium

Total Direct Costs: \$1,200,000

Role: Principal Investigator (CBC Director)

Traumatic Brain Injury National Data and Statistical Center.

PI: Cindy Harrison-Felix; 10/06-10/08

Role: Biostatistics Core leader

NIH grant (M01 RR00051). PI: Richard Krugman; 12/1978 to 03/2010.

General Clinical Research Center - Adult

Total direct costs: \$ 35,252,126

Role: Director of Biostatistics

NIH grant (P50 CA58184). PI: Paul Bunn; 09/1992 to 04/2006.

SPORE in Lung Cancer

Total direct costs: \$7,480,330

Role: Co-Director of Biostatistics Core

NIH grant (R18 DK064997-01). PI: Julie Marshall; 9/1/03 to 8/31/08

Family-based Prevention of Diabetes & Its Complications

Total direct costs: \$3,073,143

Role: Co-Investigator (Trial Biostatistician).

NIH grant (R01 HL069719). PI: Scott Emerson; 09/2001 to 08/2004.

Group Sequential Methods for Longitudinal Endpoints

Total direct costs: \$300,000

Role: PI on subcontract to UCD (provided 20% salary support)

Publications

Refereed Journal Articles:

- Shimm, D., **Kittelson**, J., Oleson, J., Aristizabal, S., Barlow, L., Cetas, T. Interstitial Thermoradiotherapy: Thermal Dosimetry and Clinical Results. *Int. J. Radiat. Oncol. Biol. Phys.* V.18:383-387 (1990).
- Yanes, G.A., Obbens, E., **Kittelson**, J. Assessment of Cancer Pain in Outpatients Undergoing Radiation Therapy. *Pain Suppl.* 5:S164 (1990).
- Nagle, R., Brawer, M., **Kittelson**, J., Clark, V. Phenotypic Relationships of Prostatic Intraepithelial Neoplasia To Invasive Prostatic Carcinoma. *Am. J. Pathology* V.138:119-128 (1991).
- Wilder, R., Shimm, D., **Kittelson**, J., Rogoff, E., Cassady, J. Recurrent Basal Cell Carcinoma Treated With Radiation Therapy. *Arch. Dermatology* Vol. 127, pp 1668-1672 (1991).
- Wilder, R.B., **Kittelson**, J., Shimm, D.S. Basal-cell Carcinoma Treated with Radiation-Therapy. *Cancer* V.68(10):2134-2137 (1991).
- Friedman, D., Knox, J.D., Siadatpajouh, M., **Kittelson**, J., Navre, M., Bowden, T., Nagle, R.B., Stetlerstevenson, W. Collagenase Expression in Normal Prostate, PIN, and Invasive Prostatic-Carcinoma. *Clinical Research* V.40(1): A63 (1992).
- Wilder, R., Buatti, J., **Kittelson**, J., Shimm, D., Harari, P., Rogoff, E., Cassady, J. Pterygium Treated With Excision and Postoperative Beta Irradiation. *Int. J. Radiat. Oncol. Biol. Phys.* V.23:533-537 (1992).
- Stea, B., **Kittelson**, J., Cassady, J., Hamilton, A., Guthkelch, N., Lulu, B., Obbens, E., Rossman, K., Shapiro, W., Shetter, A., Cetas, T. Treatment of Malignant Gliomas With Interstitial Irradiation and Hyperthermia. *Int. J. Radiat. Oncol. Biol. Phys.* V.24:657-667 (1992).
- Croghan, M.K., Shimm, D.S., Hynynen, K.H., Anhalt, D.P., Valencic, S.L., Fletcher, A.F., **Kittelson**, J.M., Cetas, T.C. A Phase-I Study of Regional Hyperthermia with Systemic Warming. *Am J. Clinical Oncology - Cancer Clinical Trials* V.16(4):354-358 (1993).

Refereed Journal Articles (con't):

- Mack, C., Stea, B., **Kittelson**, J., Shimm, D., Sneed, P., Phillips, T., Swift, P., Luk, K., Stauffer, P., Chan, K., Steeves, R., Cassady, J., Cetas, T. Interstitial Thermoradiotherapy with Ferromagnetic Implants for Locally Advanced and Recurrent Neoplasms. *Int. J. Radiat. Oncol. Biol. Phys.* V.27:109-115 (1993).
- Powell, W., Knox, J., Navre, M., Grogan, T., **Kittelson**, J., Nagle, R., Bowden, G.T. Expression of the Metalloproteinase Matrilysin in DU-145 Cells Increases Their Invasive Potential In Severe Combined Immunodeficient Mice. *Cancer Res.* V.53:417-422 (1993).
- Gensler, H.L., Gerrish, K.E., Williams, T., **Kittelson**, J. Prevention of Photocarcinogenesis and UV-induced Immunosuppression in Mice by Topical Tannic-Acid. *Nutrition and Cancer* V22(2):121-130 (1994).
- Makar, R., Mason, A., **Kittelson**, J., Bowden, G.T., Cress, A., Nagle, R. Immunohistochemical Analysis of Cathepsin D in Prostate Carcinoma. *Modern Pathology* V.7:747-751 (1994).
- Stea, B., Rossman, K., **Kittelson**, J., Lulu, B., Shetter, A., Cassady, J.R., Hamilton, A. A Comparison of Survival Between Radiosurgery and Stereotactic Implants for Malignant Astrocytomas. *Acta Neurochir.* V.62:47-54 (1994).
- Stea, B., Rossman, K., **Kittelson**, J., Shetter, A., Hamilton, A., Cassady, J.R. Interstitial Irradiation Versus Interstitial Thermoradiotherapy for Supratentorial Malignant Gliomas: A Comparative Survival Analysis. *Int. J. Radiat. Oncol. Biol. Phys.* V.30:591-600 (1994).
- Leigh, B., Stea, B., Cassady, J.R., **Kittelson**, J., Cetas, T. Clinical Hyperthermia With a New Device: The Current Sheet Applicator. *Int. J. Radiat. Oncol. Biol. Phys.* V.30:945-951 (1994).
- Tsang, T., Chu, Y., Powell, M., **Kittelson**, J., Mead-Tollin, L., Bos, T., Hendrix, M., Bowden, G.T. *V-jun* Oncogene Suppressed Both Porbol Ester Induced Cell Invasion and Stromelysin Gene Expression in a Mouse Papilloma Cell Line. *Cancer Res.* V.54:882-886 (1994).
- Toglia, A., **Kittelson**, J., Roemer, R., Hodak, J., Carter L. Cerebral bloodflow in and around spontaneous malignant gliomas. *Int. J. Hyperthermia.* V.4:461-476 (1996).
- Feinberg, W.M., Erickson, L.P., Bruck, D., **Kittelson**, J.M. Hemostatic markers in acute ischemic stroke: Association with stroke type, severity, and outcome. *Stroke* V.27(8):1296-1300 (1996).
- Emerson, S.S., **Kittelson**, J.M. A computationally simpler algorithm for the UMVUE of a normal mean following a group sequential test. *Biometrics* V.53(1):365-9 (1997).
- Molteno, A.C.B., Bosma, N.J., **Kittelson**, J.M. Otago Glaucoma Surgery outcome study. Long-term result of trabeculectomy 1976-1995. *Ophthalmology* V.106(9):1742-50 (1999).

Refereed Journal Articles (con't):

- Kittelsohn**, J.M., Emerson, S.S. A unifying family of group sequential test designs. *Biometrics* V.55(3):874-882 (1999).
- Kay, I.P., **Kittelsohn**, J.M., Stewart, R.A.H. Relationship between duration and intensity of first exercise and 'warm-up' in ischaemic heart disease. *Heart* V.83(1):17-21 (2000).
- Kay, I.P., **Kittelsohn**, J.M., Stewart, R.A.H. Collateral recruitment and "warm-up" after first exercise in ischemic heart disease. *American Heart Journal* V.140(1):121-5 (2000).
- Stewart, R.A.H., **Kittelsohn**, J.M., Kay, I.P. Statistical methods to improve the precision of the treadmill exercise test. *J. American College of Cardiology* V.36(4):1274-79 (2000).
- Eberhart-Phillips, J., **Kittelsohn**, J.M., Meningococcal vaccine (letter). *New Zealand Medical Journal* V.114(1139):413 (2001).
- Jones, S.L., **Kittelsohn**, J.M., Cowan, J.O., Flannery, E.M., Hancox, R.J., McLachlan, C.R., Taylor, D.R. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. *Am. J. of Respiratory and Critical Care Medicine* V.164(5):738-743 (2001).
- Delahunt, B., **Kittelsohn**, J.M., McCredie, M.R.E., Reeve, A.E., Stewart, J.H., Bilous, A.M. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma. Assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. *Cancer* V.94(3):658-664 (2002).
- Kittelsohn**, J.M., Kieser, J.A., Buckingham, D.M., Herbison, G.P. Weighing evidence: quantitative measures of the importance of bite mark evidence. *J. Forensic Odontostomatology* V.20(2):31-37 (2002).
- Varella-Garcia, M., **Kittelsohn**, J., Schulte, A.P., Vu, K.O., Wolf, H.J., Zeng, C., Hirsch, F.R., Byers, T., Franklin, W.A. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. *Cancer Detection and Prevention*. V.28:244-51 (2004).
- Perreault, L., Lavelly, J.M., **Kittelsohn**, J.M., Horton, T.J. Gender differences in lipoprotein lipase activity after acute exercise. *Obes Res* V12(2):241-249 (2004).
- Kittelsohn**, J.M., Sharples, K., Emerson, S.S. Group Sequential Clinical Trials for Longitudinal Data with Analyses Using Summary Statistics. V.24:2457-2475 *Statistics in Medicine* (2005).
- Alonzo, T.A., **Kittelsohn**, J.M. A novel design for estimating relative accuracy of screening tests when complete disease verification is not feasible. *Biometrics* 62(2):605-12 (2006).

Refereed Journal Articles (con't):

- Merrick DT, **Kittelson J**, Winterhalder R, Kotantoulas G, Ingeberg S, Keith R, Kennedy T, Miller Y, Franklin W, Hirsch F. Analysis of C-erb-B1 (EGFR) and C-erb-B2 (HER2) expression in bronchial dysplasia: Evaluation of potential targets for chemoprevention of lung cancer. *Clinical Cancer Research* 12 (7 pt 1):2281-8 (2006).
- Quan D, Hammack BN, **Kittelson J**, Gilden D. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valcyclovir. *Archives of Neurology* 63(7):940-2 (2006).
- Jankowski CM, Gozansky WS, Schwartz RS, Dal DJ, **Kittelson JM**, Scott SM, VanPelt RE, Kohrt WM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. *J Clin Endocrinol Metab.* 2006 Aug;91(8):2986-93.
- Bhatia SS, Majka DS, **Kittelson JM**, Parrish LA, Ferucci ED, Deane KD, Arend WP, Rewers M, Holers VM, Norris JM. Rheumatoid factor positivity is inversely associated with oral contraceptive use in women without rheumatoid arthritis. *Ann Rheum Dis.* (2007) 66(2):267-9.
- Emerson, S.S., **Kittelson, J.M.**, Gillen, D.L. Bayesian evaluation of group sequential clinical trial designs. *Statistics in Medicine.* (2007) Mar;26(7):1431-49.
- Emerson, S.S., **Kittelson, J.M.**, Gillen, D.L. Frequentist evaluation of group sequential clinical trial designs. *Statistics in Medicine.* (2007) 26(28): 5047-80.
- Miller YE, Blatchford P, Hyun DF, Keith RL, Kennedy TC, Wolf H, Byers T, Bunn PA Jr, Lewis MT, Franklin WA, Hirsch FR, **Kittelson J**. Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease. *Cancer Epidemiol Biomarkers Prev.* (2007) 16(11):2425-31.
- Jha A, Weintraub A, Allshouse A, Morey C, Cusic C, **Kittelson J**, Harrison-Felix C, Whiteneck G, Gerber D. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. *J Head Trauma Rehabil* (2008) 23(1):52-63.
- Jankowski CM, Gozansky WS, **Kittelson JM**, Van Pelt RE, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediate by serum estrogens. *J Clin Endocrinol Metab* (2008) 93(12) 4767-73.
- Kelly K, **Kittelson JM**, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer. *Cancer Prevention Research* (2009) 2(5) 440-49.

Refereed Journal Articles (con't):

- Berger JS, Krantz MJ, **Kittelson JM**, Hiatt WR. Aspirin for the prevention of cardiovascular events among patients with peripheral artery disease: a meta-analysis of randomized trials. *JAMA* (2009) 301(18) 1909-19.
- Kittelson JM**, Krantz MJ, Hiatt WR. Aspirin for the prevention of cardiovascular events among patients with peripheral artery disease (letter) . *JAMA* (2009) 302(11) 1165-66.
- Lowery JT, Byers T, **Kittelson JM**, Hokanson JE, Mouchawar J, Lewin J, Merrick D, Hines L, Singh M. Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter? *Breast Cancer Res Treat* (2011) 129(1) 211-9.
- Hernandez TL, **Kittelson JM**, Law CK, Ketch LL, Stob NR, Lindstrom RC, Scherzinger A, Stamm ER, Eckel RH. Fat comes back: Defense and redistribution of body fat following suction lipectomy in non-obese women. *Obesity* (2011) 129(7) 1388-95.
- Kittelson JM**. Invited book review: *Fundamentals of Biostatistics (7th edition)*, B. Rosner. *J Biopharmaceutical Statistics* (2011) 21(5)1046-1048.
- Keith RL, Blatchford PJ, **Kittelson JM**, Minna J, Kelly K, Massion P, Franklin WA, Mao J, Wilson DO, Merrick D, Hirsch F, Kennedy TC, Bunn PA, Geraci MW, Miller YE. Oral iloprost improves endobronchial dysplasia in former smokers. *Cancer Prevention Research* (2011) 4(6) 793-802.
- Boyd AP*, **Kittelson, JM**, Gillen, DL. Estimation of treatment effect under nonproportional hazards and covariate dependent censoring. *Statistics in Medicine*. (Dec 2012) 31(28):3504-15 (*PhD student thesis-related publication.)
- Spyropoulos AC, Goldenberg NA, Kessler CM, **Kittelson JM**, Schulman S, Turpie AGG, Cutler NR, Hiatt WR, Halperin JL; The Antithrombotic Trials Leadership and Steering Group (ATLAS). Comparative Effectiveness and Safety of the Novel Oral Anticoagulants: Do the Pivotal Clinical Trials Point to a New Paradigm? *Journal of Thrombosis and Haemostasis* (2012) 10(12):2621-4.
- Mealer M, **Kittelson J**, Thompson BT, Wheeler AP, Magee JC, Sokol RJ, Moss M, Kahn MG. Remote source document verification in two national clinical trials networks: a pilot study. *PLoS One*. 2013 Dec 5;8(12):e81890. doi: 10.1371/journal.pone.0081890. PMID: 24349149.
- Sosa LJ, Bergman J, Estrada-Bernal A, Glorioso TJ, **Kittelson JM**, Pfenninger KH. Amyloid precursor protein is an autonomous growth cone adhesion molecule engaged in contact guidance. *PLoS One*. (2013) 14;8(5):e64521. doi: 10.1371/journal.pone.0064521

Refereed Journal Articles (con't):

- Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, Wolfe P, Kohrt WM, Ruscini JM, **Kittelson JM**, Cress ME, Ballard R, Schwartz RS. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. *J Clin Endocrinol Metab.* (2013) 98(5):1891-900. doi: 10.1210/jc.2012-3695.
- Kittelson JM**, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Turpie AGG, Cutler NR, Hiatt WR, Goldenberg NA. Balancing Risk and Benefit in Venous Thromboembolism Trials: concept for a bivariate endpoint trial design and analytic approach. *J Thromb Haemost.* (2013) 11(8):1443-8. doi: 10.1111/jth.12324.
- Van Pelt RE, Gozansky WS, Wolfe P, **Kittelson JM**, Jankowski CM, Schwartz RS, Kohrt WM. Estrogen or raloxifene during postmenopausal weight loss: Adiposity and cardiometabolic outcomes. *Obesity.* (2014) 22(4):1024-31. doi: 10.1002/oby.20653.
- Bade MJ, **Kittelson JM**, Kohrt WM, Stevens-Lapsley JE. Predicting Functional Performance and Range of Motion Outcomes After Total Knee Arthroplasty. *Am J Phys Med Rehabil.* (2014) Feb 6.
- Hildreth KL, Van Pelt RE, Moreau KL, Grigsby J, Hoth KF, Pelak V, Anderson CA, Parnes B, **Kittelson J**, Wolfe P, Nakamura T, Linnebur SA, Trujillo JM, Aquilante CL, Schwartz RS. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. *Dement Geriatr Cogn Dis Extra.* 2015 Feb 20;5(1):51-63. doi: 10.1159/000371509.
- Shea KL, Gavin KM, Melanson EL, Gibbons E, Stavros A, Wolfe P, **Kittelson JM**, Vondracek SF, Schwartz RS, Wierman ME, Kohrt WM. Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment. *Menopause.* 2015 Mar 16. PMID: 25783468
- Jankowski CM, Shea K, Barry DW, Linnebur SA, Wolfe P, **Kittelson J**, Schwartz RS, Kohrt WM. Timing of Ibuprofen Use and Musculoskeletal Adaptations to Exercise Training in Older Adults. *Bone Rep.* 2015 Jan 1;1:1-8. PMID: 25642444
- Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, **Kittelson JM**, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings. *J Thromb Haemost.* (2015) Sep;13(9):1597-605. doi: 10.1111/jth.13038.
- Goldenberg NA, Takemoto CM, Yee DL, **Kittelson JM**, Massicotte MP. Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities. *Blood.* 2015 Dec 10;126(24):2541-7. PMID: 26500341

Refereed Journal Articles (con't):

- Kittelson JM**, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. *Thromb Haemost.* 2016 Sep; 23;116(3). doi:10.1160/TH15-12-1000.
- Pitts R, Gunzburger E*, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, **Kittelson J**, Schwartz GG. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. *J Am Heart Assoc.* 2017 Jan 10;6(1). doi:10.1161/JAHA.116.004119. (*Student mentee).
- Pitts R, Gunzburger E*, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Nicholls SJ, Niesor EJ, Olsson AG, Shah PK, Tardif JC, **Kittelson J**, Schwartz GG. Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. *J Am Coll Cardiol.* 2016 Dec 6;68(22):2488-2490. doi: 10.1016/j.jacc.2016.09.932. (*Student mentee).
- Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, **Kittelson J**. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. *JAMA Cardiol.* 2017 Oct 25. doi: 10.1001/jamacardio.2017.3833.
- Chi G, Goldhaber SZ, **Kittelson JM**, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. *J Thromb Haemost.* 2017 Oct;15(10):1913-1922. doi: 10.1111/jth.13783.
- Capell WH, Bonaca MP, Nehler MR, **Kittelson JM**, Anand SS, Berkowitz SD, Chen E, DeBus S, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt, WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). *Am Heart J.* 2018 May; 199:83-91. doi:10.1017/j.aha.2018.01.011.
- Manago MM, Hebert JR, **Kittelson J**, Schenkman M. Contributions of Ankle, Knee, Hip, and Trunk Muscle Function to Gait Performance in People With Multiple Sclerosis: A Cross-Sectional Analysis. *Phys Ther.* 2018 Jul 1;98(7):595-604. doi: 10.1093/ptj/pzy048.
- Manago MM, Hebert JR, **Kittelson J**, Schenkman M. Feasibility of a targeted strengthening program to improve gait in people with multiple sclerosis: a brief report. *Int J Rehabil Res.* 2018 Dec;41(4):364-367. doi: 10.1097/MRR.0000000000000306.

Refereed Journal Articles (con't):

- Nicholson LK, Pratap H, Bowers E, Gunzburger E, Bandi SR, Gardner EM, Palmer BE, Wright T, **Kittelsohn J**, Janoff EN. Effective B cell activation in vitro during viremic HIV-1 infection with surrogate T cell stimulation. *Immunobiology*. 2018 Dec;223(12):839-849. doi: 10.1016/j.imbio.2018.08.007.
- Salahuddin T, **Kittelsohn J**, Tardif JC, Shah PK, Olsson AG, Nicholls SJ, Leitersdorf E, Leiter LA, Kallend D, Black DM, Barter PJ, Ballantyne CM, Schwartz GG. *Am Heart J*. 2019 Dec 16;221:60-66. doi: 10.1016/j.ahj.2019.12.003. [Epub ahead of print] PMID: 31927126.
- Schwartz GG, Leiter LA, Ballantyne CM, Barter PJ, Black DJ, Kallend D, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, **Kittelsohn JM**. Dalcetrapib reduces risk of new onset diabetes in patients with coronary heart disease. *Diabetes Care*. 2020 May;43(5):1077-1084. doi: 10.2337/dc19-2204.
- Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, **Kittelsohn JM**, Gudiz I, Mtys L, Kriebins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. *N Engl J Med*. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052.
- Hu J, Blatchford PJ, Goldenberg NA, **Kittelsohn JM**. Group Sequential designs for clinical trials with bivariate outcomes. *Stat Med*. 2020 Nov 20;39(26):3823-3839. doi: 10.1002/sim.8696.
- Burton JR Jr, Helmke S, Lauriski S, **Kittelsohn J**, Everson GT. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. *Transl Res*. 2021 Jan 2:S1931-5244(20)30321-2. doi: 10.1016/j.trsl.2020.12.010.
- Jackson CL, Colborn K, Gao D, Rao S, Slater HC, Parikh S, Foy BD, **Kittelsohn JM**. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data. *Clin Trials*. 2021 Jul 3: online ahead of print. doi: 10.1177/17407745211028581.
- McRae MP, **Kittelsohn JM**, Helmke SM, Everson GT. Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test. *Basic Clin Pharmacol Toxicol*. 2024 Mar;134(3):385-395. doi: 10.1111/bcpt.13980. Epub 2024 Jan 15. PMID: 38225212
- McRae MP, **Kittelsohn JM**, Helmke SM, Everson GT. Within-individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test. *Clin Transl Sci*. 2024 Apr;17(4):e13786. doi: 10.1111/cts.13786. PMID: 38558534; PMCID: PMC10982894.

Refereed Journal Articles (con't):

Burton JR Jr, Helmke S, Lauriski S, **Kittelson JM**, Everson GT. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. *Transl Res.* 2021 Jul;233:5-15. doi: 10.1016/j.trsl.2020.12.010. Epub 2021 Jan 2. PMID: 33400995.

Books/Chapters:

Kittelson, J. Analysis of Flood Peak Moderation by Depressional Wetland Sites. In: *Proceedings of the International Symposium on Ecology and Management of Wetlands.* Donal Hook ed. Croom Helm LTD, U.K. (1988).

Kittelson, J. A Wetland Evaluation Methodology for the North Central United States. St. Paul District, Corps of Engineers (1988).

Shimm, D., Kittelson, J., Stea, B. Interstitial Thermoradiotherapy: The University of Arizona Experience. in Urano, M., and Douple, E. eds. *Hyperthermia and Oncology*, Vol. 3. Zeist, VSP, pp 181-198 (1991).

Stea, B., Shimm, D., Kittelson, J., Cetas, T. Interstitial Hyperthermia With Ferromagnetic Seed Implants: Preliminary Results of a Phase I Clinical Trial. In: *Interstitial Hyperthermia.* L. Handl-Zeller ed., Springer-Verlag, New York (1992).

Non-refereed journal articles and reports:

Touche, A.B., Conner, W.H., Hendricks, K., Kittelson, J., Miller, E., Patterson, S., Ray, S., Hamilton, D. Hydrology Workgroup Report. In: *Proceedings, Third Bottomland Hardwoods Workshop*, Savannah, Georgia. U.S. EPA, Wash. D.C. (1986).

Shimm, D., Hynynen, K., Anhalt, D., Cassady, J., Cetas, T., Kittelson, J., Stea, B., Sykes, H., Roemer, R. Clinical Results Using Scanned, Focussed Ultrasound for Deep Hyperthermia. *Proceedings of the 5th International Symposium on Hyperthermic Oncology*, Kyoto (1988).

Gerbig, B., Kittelson, J. Developing a State Wetland Evaluation Methodology. *Proceedings of the National Conference on Enhancing the States' Lake and Wetland Management Programs.* Chicago, Ill (1989).

Roe, D.J., Kittelson, J.M., Adair Jr, L.P. Analysis of observed versus relative tumor volumes in tumor growth experiments. *Proceedings of the Biopharm. Sect. of the American Statistical Assoc.* (1996).

Talks and Presentations:

Invited:

Invited to be workgroup chairman for the north-central United States at the Corps of Engineers Wetland Values Workshop. New Orleans, LA. Nov. 1985.

Invited to participate in the third Environmental Protection Agency Workshop on Bottomland Hardwoods. Savannah, Georgia. January 1986.

Analysis of Flood Peak Moderation by Depressional Wetland Sites. International Symposium on Ecology and Management of Wetlands. Charleston, South Carolina. June 1986.

Wetland Hydrologic Functions. Red River Valley Land and Water International Summit Conference. Grand Forks, North Dakota. November 1986

A Wetland Evaluation Methodology For the North-Central United States. 48th Annual Midwest Fish and Wildlife Conference. Omaha, Nebraska. December 1986.

A Wetland Evaluation Methodology For the North-Central United States. Minnesota Waters: 1988 conference. St. Paul, Minnesota. February, 1988.

A Database for Hyperthermia Treatment. First Annual Meeting for Computers in Radiation Oncology, Tucson Arizona. September 1988.

A Wetland Evaluation Methodology For the North-Central United States. Minnesota Dept. of Nat. Resources Waters Conference, Alexandria, Minnesota. Sep, 1989.

Design of Clinical Trials for Equipment Testing and Assessing Tumor Response. Invited Opening Address: 10th annual meeting of the North American Hyperthermia Group, New Orleans, LA. April, 1990.

Statistical Issues in Clinical Hyperthermia Research. Clinical Workshop, Sixth International Congress on Hyperthermic Oncology. Tucson, AZ. May 1992.

Description of Ferromagnetic Implant Hyperthermia Temperature Data. 14th Annual Meeting of the North American Hyperthermia Society, Nashville, TN. April 1994.

An Overview of the Statistical Aspects of Group Sequential Trials. University of Auckland Statistics Department. October 1998.

Designing Group Sequential Clinical Trials. Clinical Trials Research Unit at the University of Auckland. October 1998.

Statistical Methods for Evaluation of Screening Tests. University of Otago. November 2002.

Evaluation of Bronchial Histology as an Endpoint in a Phase II Chemoprevention Trial of 13-cis Retinoic Acid. Lung SPORE winter conference, St. Pete's Beach, Florida. February 2004.

Endpoint Definition from Bronchial Histology. Lung SPORE winter conference, Los Angeles, California. January 2006.

Invited Talks and Presentations (con't):

- Monitoring Longitudinal Endpoints in Clinical Trials with Long-term Follow-up. Eastern North American Region of the Biometrics Society Annual Meeting. Tampa Florida, March 2006.
- Improving the efficiency of the clinical evaluation of targeted chemoprevention agents. Summer SPORE meetings, Baltimore MD. July 2006.
- Group sequential clinical trials and non-ignorable incomplete data (session organizer). Western North American Region of the Biometrics Society Annual Meeting, Irvine California, June 2007.
- The problem: How sequential monitoring may introduce non-ignorable data (presenter). Western North American Region of the Biometrics Society Annual Meeting, Irvine California, June 2007.
- Monitoring bivariate endpoints in clinical trials. University of Washington; Department of Biostatistics Research Group, October 2009.
- Clinical trials: Design, implementation, and monitoring, Shanghai University Medical School. March 2010.
- Using intermediate endpoints to make interim decisions in clinical trials. Society for Clinical and Translational Science Annual Meeting, Washington DC. April 2010.
- Clinical trial networks: Considerations for improving the predictive value of positive trials. Fred Hutchinson Cancer Research Center, Seattle. September 2010.
- A Bayesian framework for the design and monitoring of clinical trials. Department of Biostatistics, Vanderbilt University, Nashville. December 2010.
- The design and monitoring of clinical trials with bivariate endpoints. Department of Biostatistics, University of Alabama, Birmingham. June 2011.
- A perspective on scientific efficiency in the discovery of targeted therapies, *International Association for Study of Lung Cancer*, Santa Monica, CA; February 2012.
- The design and monitoring of clinical trials with bivariate endpoints. *Antithrombotic Trials Leadership and Steering group*. Denver, CO. May 2012.
- The predictive value of a positive study: Public health impact of biomedical research. *Zucherman Scholar Seminar Series*, University of Arizona, Tucson. October 2012.
- Predictive value of a positive study: Public health impact of biomedical research. *Statistics Departmental Seminar Series*, Oregon State University, Corvallis, OR. October 2012.
- Predictive value of a positive trial: Implications for clinical trial networks. *Biostatistics departmental seminar*, University of Texas, Houston, TX. November 2012.

Contributed talks:

- Simulating Measures of Thermal Dose. 9th Annual Meeting of the North American Hyperthermia Group, Seattle, Washington. March 1989.
- Estimating Temperature Distributions During Hyperthermia Treatment. 150th Annual Meeting of the American Stat. Assoc., Wash., D.C. August 1989.
- The Effect of Uncertainty in Temperature Measurement on Analysis of Response. 10th annual meeting of the North American Hyperthermia Group, New Orleans, LA. April, 1990.
- Methods for Comparing Habitat Preference Curves. 1990 meetings of the Biometrics Society (WNAAR), Bozeman Montana. 1990.
- Statistical Methods for Measuring and Comparing Resource Preference. 153rd Annual Meeting of the American Stat. Assoc., Boston, MA, August 1992.
- The Design of a Phase II/III Randomized Trial of a New Medical Device Using Group Sequential Methods. 154th Annual Meeting of the American Stat. Assoc., Toronto, Canada, August 1994.
- Unification of Group Sequential Designs. 155th Annual Meeting of the American Stat. Assoc., Orlando, Florida, August 1995.
- Unification of Designs for Group Sequential Clinical Trials. 48th Annual Conference of the New Zealand Statistical Association. Auckland, New Zealand, August 1997.
- Bayesian Interpretation and Design of Group Sequential Clinical Trials. University of Colorado. July 1999.
- Bayesian Interpretation and Design of Group Sequential Clinical Trials. Joint Statistical Meetings. Baltimore Maryland, August, 1999.
- The design and implementation of group sequential trials with longitudinal endpoints. Eastern North American Region of the Biometrics Society Annual Meeting. Pittsburgh Pennsylvania, March 2004.
- Group sequential trials with longitudinal endpoints and non-discrete outcome measurement. International Biometrics Conference. Cairns Australia, July 2004. (Refereed review of abstracts).
- The use of mediation markers to identify and validate biomarkers for lung cancer risk. Joint Statistical Meetings. Toronto, Ontario, August 2004.
- Methods for considering treatment effects on multiple endpoints when defining patient response in PAH clinical trials. 5th World Symposium on Pulmonary Hypertension. Nice, France. February 2013. (Refereed review of abstracts).